Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...
ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...
Treatment Pattern and Outcome of Locally Advanced Rectal Cancer in Resource-Constrained ... affect long-term patient outcomes in patients from Brazil diagnosed with prostate cancer is currently ...
Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including ...
Six months (vs. 3 years) of androgen suppression provided inferior survival for patients with locally advanced disease. Given emerging data about the potential harms of androgen-deprivation ...
Together, they addressed 19 critical questions related to prostate cancer management, including screening, biopsy techniques, handling localized and locally advanced disease, biochemical ...
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...
Prostate cancer cells usually require male androgen hormones, such as testosterone, to grow. Androgen deprivation therapy ...
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
localised or locally advanced prostate cancer [ID6215] Technology appraisal guidance TBC Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172] Technology appraisal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback